Article Text

A10.17 Interleukin-20 serum levels correlate with disease activity in rheumatoid arthritis patients and decrease in response to rituximab treatment
  1. L Vernerová1,
  2. L Andrés Cerezo1,
  3. H Hulejová1,
  4. K Pavelka1,2,
  5. J Vencovský1,2,
  6. L Šenolt1,2
  1. 1Institute of Rheumatology, Prague, Czech Republic
  2. 2Department of Rheumatology, First Faculty of Medicine, Charles University in Prague, Czech Republic


Background and objectives Interleukin 20 (IL-20), a member of IL-10 cytokine family, is a pleiotropic cytokine promoting inflammation, angiogenesis, chemotaxis and is implicated in the pathogenesis of rheumatoid arthritis (RA). In this study, serum levels of IL-20 were analysed in relation to disease activity and response to therapy in active patients with established RA who started biologic therapy with rituximab (RTX).

Materials and methods IL-20 serum levelswere analysed in 27 RA patients (24 females) at baseline and after 16 weeks of treatment; and in 49 age- and sex-matched healthy individuals. RA disease activity at baseline and after the treatment was assessed using DAS-28, CRP levels, erythrocyte sedimentation rate (ESR), total swollen joint count (SJC) and tender joint count (TJC). IL-20 serum concentrations were analysed by ELISA.

Results Baseline levels of IL-20 were significantly higher in RA patients compared to healthy individuals [73.54 (38.69–172.0)vs. 27.55 (15.42–72.92) pg/ml, p < 0.0024] and decreased after 16 weeks of RTX therapy [from 73.54 (38.69–172.0) to 61.94 (31.48–103.8) pg/ml, p = 0.040]. When analysed separately according to presence of autoantibodies, the decrease in IL-20 after RTX therapy was significant only in seropositive (RF+ and ACPA+, N = 20) patients [from 75.11 (44.70–180.9) to 61.94 (31.48–103.8), p = 0.043], but not in seronegative patients [from 51.53 (7.25–107.8) to 63.35 (23.30–102.9), p = 0.625]. Moreover, baseline IL-20 levels significantly correlated with DAS28 (r = 0.491, p = 0.008), CRP (r = 0.507, p = 0.006), ESR (r = 0.422, p = 0.025) and SJC (r = 0.376, p = 0.049).

Conclusions Circulating IL-20 levels are higher in RA patients compared to healthy individuals, correlate with disease activityand decrease in response to RTX therapy in seropositive patients. Based on these data, it can be speculated that IL-20 plays a role in RA pathology and is influenced by B cell depleting therapy.

Acknowledgements project of MHCR for conceptual development of a research organisation (00023728).

Key words
  • rheumatoid arthritis
  • interleukin-20
  • disease activity
  • proinflammatory cytokines

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.